Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Receivables: 2019-2024

Historic Receivables for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $972,000.

  • Silence Therapeutics' Receivables fell 92.52% to $28,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 91.42%. This contributed to the annual value of $972,000 for FY2024, which is 235.17% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Receivables is $972,000, which was up 235.17% from $290,000 recorded in FY2023.
  • Silence Therapeutics' 5-year Receivables high stood at $37.6 million for FY2020, and its period low was $290,000 during FY2023.
  • Over the past 3 years, Silence Therapeutics' median Receivables value was $972,000 (recorded in 2024), while the average stood at $798,137.
  • Its Receivables has fluctuated over the past 5 years, first soared by 94,976.56% in 2020, then crashed by 98.79% in 2021.
  • Yearly analysis of 5 years shows Silence Therapeutics' Receivables stood at $37.6 million in 2020, then plummeted by 98.79% to $455,416 in 2021, then spiked by 148.65% to $1.1 million in 2022, then tumbled by 74.39% to $290,000 in 2023, then skyrocketed by 235.17% to $972,000 in 2024.